NDAQ:ATOS) Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing ...

The 1976 movie All the President's Men perhaps provided one of the best three-word investing strategies around: "Follow the ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Lilly’s current offerings include Verzenio for early and metastatic breast cancers. Verzenio, which Lilly has heavily advertised in recent years, is a top seller for Lilly, with sales of almost ...